跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 22,643 条关于
“ApoC-III”
全部
22,643
临床试验
17,203
药物
610
机构
46
资讯
4,784
9个月前
FDA Approves Plozasiran for Familial Chylomicronemia Syndrome, Marking Breakthrough in Rare Lipid Disorder Treatment
8个月前
Amarin Reports Strong Q4 2025 Performance as VASCEPA/VAZKEPA Franchise Positioned to Benefit from Emerging Triglyceride Therapies
9个月前
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
去年
Ionis Reports Positive Phase 3 Results for Olezarsen in Hypertriglyceridemia
2年前
FDA Grants Priority Review to Ionis' Olezarsen for Familial Chylomicronemia Syndrome
8个月前
Sanofi Secures Chinese Approval for Two Breakthrough Therapies Targeting Rare Cardiovascular and Metabolic Disorders
去年
Ionis Reports Positive Phase 3 Results for Olezarsen in Familial Chylomicronemia Syndrome
10个月前
Arrowhead Pharmaceuticals Secures First FDA Approval with Redemplo for Rare Genetic Disorder
2年前
Retatrutide Shows Promise in Improving Lipid and Cardiovascular Risk Profile
去年
FDA Gears Up for Year-End Decisions on Novel Therapies for Rare Diseases and Cancer
第 1 页,共 479 页
上一页
下一页